Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

November 30, 2015

Study Completion Date

July 18, 2016

Conditions
Relapsed T-Cell Acute Lymphoblastic LeukemiaRelapsed T-Cell Lymphoblastic Lymphoma
Interventions
DRUG

Nelarabine

Dose will be assigned at study entry. Nelarabine will be given IV over 60 minutes (given at hours 0 to 1) on days 1 through 5.

DRUG

Etoposide

100 mg/m2/day IV over 2 hours (given at hours 1 to 3) on days 1 through 5

DRUG

Cyclophosphamide

Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.

DRUG

Methotrexate

"Give between day 29 and 36 or when ANC\>750 and PLTS\>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.~Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but \<2 years of age 10 mg for patients age greater than or equal to 2, but \<3 years of age 12 mg for patients greater than or equal to 3, but \< 9 years of age 15 mg for patients greater than or equal to \>9 years of age"

DRUG

Filgrastim

5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000/mm3 for two consecutive days.

Trial Locations (37)

10016

New York University Medical Center, New York

10032

Children's Hospital New York-Presbyterian, New York

28203

Levine Children's Hospital at Carolinas Medical Center, Charlotte

33136

University of Miami Cancer Center, Miami

64108

Children's Mercy Hospitals and Clinics, Kansas City

80045

The Children's Hospital, University of Colorado, Aurora

90027

Childrens Hospital Los Angeles, Los Angeles

98105

Seattle Children's Hospital, Seattle

Unknown

Children's Hospital Orange County, Orange

Children's National Medical Center, Washington D.C.

Children's Healthcare of Atlanta, Emory University, Atlanta

Lurie Children's Hospital, Chicago

Johns Hopkins University, Baltimore

Dana Farber, Boston

Rainbow Babies, Cleveland

Nationwide Childrens Hospital, Columbus

Oregon Health and Science University, Portland

Vanderbilt Children's Hospital, Nashville

University of Texas at Southwestern, Dallas

Cook Children's Hospital, Fort Worth

Primary Children's, Salt Lake City

Medical College of Wisconsin, Milwaukee

Children's Hospital at Westmead, Westmead

Royal Children's Hospital, Brisbane

Royal Children's Hospital, Melbourne, Melbourne

Sydney Children's Hospital, Sydney

St. Anna Children's Hospital, Vienna

Hospital for Sick Kids, Toronto

Sainte Justine University Hospital, Montreal

British Columbia Children's Hospital, Vancouver

CHU Lille, Lille

Bambino Gesù Hospital, Rome

Erasmus MC - Sophia, Rotterdam

94143-0106

UCSF School of Medicine, San Francisco

48109-0914

C.S. Mott Children's Hospital, Ann Arbor

55404-4597

Childrens Hospital & Clinics of Minnesota, Minneapolis

38105-3678

St. Jude, Memphis

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

Therapeutic Advances in Childhood Leukemia Consortium

OTHER